



Determination of HbA1c values with high performance liquid chromatography (HPLC) occasionally reveals hemoglobin anomalies with no or minimal 
clinical evidence. We coincidentally detected two cases of Hb Hasharon, an alpha globin gene mutation, in two heterozygous patients and one case 
of Hb NYU, a delta globin gene mutation, in another patient. Both anomalies have not been described in subjects of German origin to date. Characte-
rization was carried out with HPLC, hemoglobin electrophoresis, capillary zone electrophoresis, DNA sequencing, complete blood count and clinical 
chemical analysis.
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Introduction
Hereby we report two hemoglobin anomalies not 
previously described in subjects of Central Euro-
pean origin, namely hemoglobin Hasharon, an al-
pha chain variant, in two non-related patients, and 
hemoglobin NYU, a delta chain variant, in one pa-
tient. The patients were treated at the University 
Clinics Bonn for illnesses unrelated to these hemo-
globin anomalies. The attending physicians had 
requested HbA1c analysis, which we performed in 
our laboratory using high performance liquid 
chromatography (HPLC) (Variant, Biorad).
Hb Hasharon [α(2)47(CD5)Asp→Hisβ2] is a hemo-
globin anomaly with a mutation in the alpha 
globin. It was fi rst described in 1968 as Hb Sinai in 
a family of Jewish origin (1). In the literature, spo-
radic incidences of Hb Hasharon have been report-
ed from Israel, Italy, Greece and in Latin Americans 
of Mediterranean origin (2-4). We detected 
heterozygous Hb Hasharon in a 60-year old female 
patient and a 74-year old male patient. Both pa-
tients have German ancestors.
Hb NYU [δ12(A9)Asn→Lys] is a hemoglobin anom-
aly with a mutation in the delta globin. It was fi rst 
described in 1969 in two families of Russian-Jewish 
origin (5). In the literature, this mutation has to date 
been reported in Jewish patients and patients of 
Italian and Greece origin (6,7). We detected Hb NYU 
in a 72-year old female patient of German origin. 
Materials and methods
The study was performed at the University hospi-
tal Bonn from July 2010 until October 2010. 
Through informed consent we obtained EDTA-
blood and serum from all patients. Hemolysates 
from EDTA-blood were analyzed for high perfor-
mance liquid chromatography analysis, capillary 
zone electrophoresis and hemoglobin electropho-
resis. EDTA-blood was analyzed for gene sequenc-
ing on a genetic analyzer and for blood cell counts. 
Serum samples were analyzed for serum iron, fer-
ritin, soluble transferrin receptor, haptoglobin, lac-
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tate dehydrogenase, aspartate amino transferase 
and potassium on a clinical chemistry analyzer.
HPLC was performed with the Beta-Thal program 
of Variant II (Biorad, Munich, Germany). Hemoglo-
bin electrophoresis in the acidic and the alkaline 
range was carried out with the Hydrasys system 
(Sebia, Fulda, Germany) and hemoglobin capillary 
zone electrophoresis with the Capillarys system 
(Sebia, Fulda Germany). Complete blood count 
was analyzed with the XE-5000 analyzer (Sysmex, 
Norderstedt, Germany), clinical chemical analysis 
was carried out with Dimension Vista 1500 (Sie-
mens, Eschborn, Germany).
DNA was isolated from peripheral blood leuko-
cytes. Polymerase chain reaction (PCR) and gene 
sequencing of alpha, beta and delta globins was 
performed by standard procedures. In brief, hu-
man α1- and α2-globin genes (HBA1, HBA2) were 
selectively amplifi ed with a universal forward 
primer (5’-CCAAGCATAAACCCTGGCGC-3’) and a 
reverse primer complementary to a nonhomolo-
gous part of their 3’ untranslated region (α1: 5’-
CACGGGGGTACGGGTGCAG-3’;  α2: 5’-AG-
GAAGGGCCGGTGCAAGG-3’). The HBB gene was 
amplifi ed with primers 5’-GTCAGGGCAGAGCCA-
TCTATT-3’ and 5’-GCACTGACCTCCCACATTCC-3’ 
and, in case of the HBD gene, primers 5’-CACTG-
GAGCAGGGAGGACAG-3’ and 5’-AAGCCATACCCTT-
GAAGTAGGC-3’ were used. PCR primers also served 
as sequencing primers using a 3130/x genetic ana-
lyzer (Applied Biosystems, Darmstadt, Germany). 
Results
Hb Hasharon
In the female patient, the complete blood count 
was normal with RBC 5.0 x 1012/L (4.1-5.1 x 1012/L), 
Hb 14.3 g/dL (12.3-15.3 g/dL), hematocrit 0.41 L/L 
(0.35-0.47 L/L), MCV 83 fL (80-96 fL), MCH 29 pg (27 
– 34 pg); clinical chemical analysis revealed normal 
haptoglobin values, there was no indication of 
hemolysis and ferritin value was within the refer-
ence range. HPLC showed an 18.2% peak at 4.17 
minutes retention time. Capillary zone electropho-
resis showed a peak of 20.5% in zone 4 and a small 
peak of 0.5% in zone 1. Hemoglobin electrophore-
sis revealed in the acidic range a band directly af-
ter HbA0 to the anode. In the alkaline range, a 
band was apparent directly after in direction to 
the anode (Figure 1). Gene sequencing resulted in 
[α(2)47(CD5)Asp→Hisβ2]. In the male patient, the 
complete blood count was also normal with RBC 
3.9 x 1012/L (4-5.65 x 1012/L), Hb 13.3 g/dL (12.5-17.2 
g/dL), hematocrit 39% (37-49%), MCV 99 fL (80-101 
fL), MCH 34 pg (27-34 pg). In both patients, con-
comitant alpha-thalassemia could be excluded. 




















































The patient’s complete blood count was normal 
with RBC 4.6 x 1012/L (3.85-5.2 x 1012), Hb 13.4 g/dL 
(11.8-15.8 g/dL), hematocrit 0.41 L/L (0.355-0.455 
L/L), MCV 89 fL (80-101 fL), MCH 29 pg (27-34 pg). 
Clinical chemical analysis revealed normal hapto-
globin levels and there was no indication of hemo-
lysis, while ferritin value was normal. In HPLC, a 
1.1% peak was noted at 3.65 minutes retention 
FIGURE 1. Capillary zone electrophoresis (B), acidic Hb electrophoresis (C) and alkaline Hb electrophoresis (D). 
time. In capillary zone electrophoresis, a peak of 
0.9% was noted between zone 1 and zone 2 as 
well as a low HbA2 of 1.2%. In hemoglobin electro-
phoresis, a band was noted in the acidic range di-
rectly after HbA0 to the cathode, while in the alka-
line range, a band was noted directly after the 
HbA0 band to the anode (Figure 2). Gene sequenc-
ing resulted in [δ12(A9)ASN→Lys].
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Hb Hasharon is a hemoglobin variant with an al-
pha globin mutation with no clinical relevance (8). 
However, with concomitant alpha-thalassemia it 
can lead to hemolytic anemia (3). In both of our 
patients, clinical chemical laboratory parameters 
as well as complete blood count were normal. 
Also, no hemolysis was found. Hb NYU is a rare he-
moglobin anomaly with the delta globin gene af-
fected. In healthy adults, delta globin is only pres-
ent in the HbA2 fraction, which normally consti-
tutes up to a maximum of 3.5% of total hemoglo-
bin. Clinically relevant cases of anemia or hemoly-
sis have only been described with concomitant 
thalassemia (9). In our female patient, all clinical 
chemical parameters as well as the complete blood 
count were normal. Hemoglobin Hasharon and 
hemoglobin NYU have to date only been reported 
in patients of Jewish and/or Mediterranean origin. 
Following intensive research, our patients con-
fi rmed their German origin with no ancestors of 
Jewish or Mediterranean origin. No hemoglobin 
anomaly had been reported in any of the families. 
Unfortunately, due to the advanced age of our pa-
tients we were unable to analyze blood from im-
mediate ancestors. 
Neither Hb Hasharon nor Hb NYU have been re-
ported in subjects of German origin to date.
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FIGURE 2. Capillary zone electrophoresis (B), acidic Hb electrophoresis (C) and alkaline Hb electrophoresis (D).
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Hemoglobin Hasharon i hemoglobin NYU kod ispitanika njemačkog porijekla
Sažetak
Određivanjem koncentracije HbA1c metodom tekućinske kromatografi je visoke djelotvornosti (engl. high performance liquid chromatography, 
HPLC) povremeno se otkriju anomalije hemoglobina bez ili s vrlo malo kliničkih manifestacija. Slučajno smo otkrili dva slučaja Hb Hasharon, 
genske mutacije alfa globina kod dva heterozigotna bolesnika i jedan slučaj Hb NYU, genske mutacije delta globina kod drugog bolesnika. Obje 
anomalije nađene su kod ispitanika njemačkog porijekla. Karakterizacija je izvršena metodom HPLC, elektroforezom hemoglobina, kapilarnom 
zonskom elektroforezom, DNA sekvenciranjem, kompletnom krvnom slikom i kliničko kemijskom analizom.
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